Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

The role of positron emission tomography in pharmacokinetic analysis.

Fischman AJ, Alpert NM, Babich JW, Rubin RH.

Drug Metab Rev. 1997 Nov;29(4):923-56. Review.

PMID:
9421680
2.

Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.

Fischman AJ, Alpert NM, Rubin RH.

Clin Pharmacokinet. 2002;41(8):581-602. Review.

PMID:
12102642
3.

Positron emission tomography (PET): expanding the horizons of oncology drug development.

Hammond LA, Denis L, Salman U, Jerabek P, Thomas CR Jr, Kuhn JG.

Invest New Drugs. 2003 Aug;21(3):309-40. Review.

PMID:
14578681
4.

[Neuropharmacology and receptor studies in the elderly].

Meltzer CC.

Rev Neurol. 2002 Oct 16-31;35(8):767-77. Review. Spanish.

5.

Modeling of PET data in CNS drug discovery and development.

Varnäs K, Varrone A, Farde L.

J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):267-79. doi: 10.1007/s10928-013-9320-6. Epub 2013 May 10. Review.

PMID:
23660778
6.

Fundamentals of positron emission tomography and applications in preclinical drug development.

Cherry SR.

J Clin Pharmacol. 2001 May;41(5):482-91. Review.

PMID:
11361044
7.

Measuring receptor occupancy with PET.

Waarde Av.

Curr Pharm Des. 2000 Nov;6(16):1593-610. Review.

PMID:
10974155
8.

Positron emission tomography in drug development.

Rubin RH, Fischman AJ.

Q J Nucl Med. 1997 Jun;41(2):171-5.

PMID:
9203856
9.

[The role of positron emission tomography in neuropharmacology in the living human brain and drug development].

Yanai K, Tagawa M.

Nihon Rinsho. 2000 Oct;58(10):2149-57. Review. Japanese.

PMID:
11068462
10.

PET and drug research and development.

Fowler JS, Volkow ND, Wang GJ, Ding YS, Dewey SL.

J Nucl Med. 1999 Jul;40(7):1154-63. Review.

11.

Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans.

Langer O, Mitterhauser M, Brunner M, Zeitlinger M, Wadsak W, Mayer BX, Kletter K, Müller M.

Nucl Med Biol. 2003 Apr;30(3):285-91.

PMID:
12745020
12.

Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

Fischman AJ, Alpert NM, Livni E, Ray S, Sinclair I, Callahan RJ, Correia JA, Webb D, Strauss HW, Rubin RH.

Antimicrob Agents Chemother. 1993 Jun;37(6):1270-7.

13.

[Significance of imaging biomarkers in exploratory clinical trials].

Takano H, Suhara T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2009 Apr;29(2):55-9. Review. Japanese.

PMID:
19562942
14.

Radioligand studies: imaging and quantitative analysis.

Lammertsma AA.

Eur Neuropsychopharmacol. 2002 Dec;12(6):513-6. Review.

PMID:
12468014
15.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
16.

Application of cardiac molecular imaging using positron emission tomography in evaluation of drug and therapeutics for cardiovascular disorders.

Yoshinaga K, Chow BJ, dekemp RA, Thorn S, Ruddy TD, Davies RA, DaSilva JN, Beanlands R.

Curr Pharm Des. 2005;11(7):903-32. Review.

PMID:
15777243
17.

Imaging drug delivery and drug responses in the lung.

Dolovich M, Labiris R.

Proc Am Thorac Soc. 2004;1(4):329-37. Review.

PMID:
16113454
18.

[Clinical evaluation of CNS drugs with PET].

Takano A.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2009 Apr;29(2):61-5. Review. Japanese.

PMID:
19562943
19.

Pharmacokinetic considerations in the PET and SPECT evaluation of CNS receptors.

Mazière B, Delforge J.

Q J Nucl Med. 1997 Jun;41(2):119-26.

PMID:
9203851
20.

Autoradiography with positron emitting isotopes in positron emission tomography tracer discovery.

Bergström M, Awad R, Estrada S, Mälman J, Lu L, Lendvai G, Bergström-Pettermann E, Långström B.

Mol Imaging Biol. 2003 Nov-Dec;5(6):390-6.

PMID:
14667493

Supplemental Content

Support Center